Clinical Trials Logo

Filter by:
NCT ID: NCT00124527 Completed - Thyroid Cancer Clinical Trials

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Start date: March 31, 2005
Phase: Phase 2
Study type: Interventional

Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer.

NCT ID: NCT00123916 Completed - Heart Disease Clinical Trials

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

BENEFIT
Start date: November 2004
Phase: Phase 3
Study type: Interventional

Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.

NCT ID: NCT00123565 Completed - Clinical trials for Coronary Atherosclerosis

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction

SHINE
Start date: December 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.

NCT ID: NCT00123487 Completed - Clinical trials for Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).

NCT ID: NCT00123474 Completed - Clinical trials for Myeloid Leukemia, Chronic, Chronic-Phase

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).

NCT ID: NCT00122837 Completed - Anxiety Disorder Clinical Trials

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Start date: April 2005
Phase: Phase 3
Study type: Interventional

This is a clinical trial assessing duloxetine and comparator to placebo in patients who have generalized anxiety disorder.

NCT ID: NCT00121979 Completed - HIV Infections Clinical Trials

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

Start date: September 2004
Phase: Phase 2
Study type: Interventional

Racivir ® (RCV) is an experimental drug which means it is not approved for use by the United States Food and Drug Administration (FDA), but it can be used in research studies like this one. RCV (Racivir®) is part of a class of drugs known as "Nucleoside Reverse Transcriptase Inhibitors" (NRTIs), which are intended to block a further increase in the amount of HIV virus in the body. Laboratory research suggests that RCV (Racivir®) may be effective in patients who have developed resistance to other NRTIs, particularly 3TC (lamivudine, Epivir®). However, a study of RCV (Racivir®) has not been done with patients who have previously been treated with other HAART (Highly Active Antiretroviral Therapy -- taking multiple HIV drugs at once) medications including 3TC (lamivudine, Epivir®). The purpose of this study is to evaluate the safety and effectiveness of RCV (Racivir®) when used together with other HIV drugs in people who have previously been treated with 3TC (lamivudine, Epivir®) and are failing with their current HAART treatments. This study will include a total of 60 HIV infected, HAART-experienced subjects currently receiving 3TC (lamivudine, Epivir®) as part of their HAART therapy. The study will take place at approximately 11 study sites in the US and Latin America.

NCT ID: NCT00121667 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone

NCT ID: NCT00121368 Completed - Smoking Clinical Trials

GN Tobacco Use Survey

Start date: February 2004
Phase: N/A
Study type: Observational

Smoking can contribute to many health problems for mothers and their babies. In developing countries, there is little information about the number of pregnant women that smoke and the reasons why some pregnant women choose to smoke. The purpose of this multi-site tobacco use survey is to obtain information on knowledge, attitudes and behaviors among pregnant women in diverse populations regarding tobacco products.

NCT ID: NCT00117598 Completed - Lymphoma Clinical Trials

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

OPTIMAL
Start date: May 2005
Phase: Phase 3
Study type: Interventional

This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).